Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Molecular diagnostics group Yourgene Health said it had launched its first oncology product.
The Elucigene DPYD assay was a chemotoxicity diagnostic assay that could identify cancer patients with Dihydropyrimidine Dehydrogenase deficiency.
The condition can cause severe and sometimes lethal side effects in patients being treated with chemotherapeutic drug 5-Fluorouracil, commonly used in the treatment of colon, oesophageal, stomach, pancreatic, breast and cervical cancers.